<DOC>
	<DOC>NCT00460850</DOC>
	<brief_summary>This single arm study will evaluate the efficacy and safety of PEGASYS in patients with lamivudine resistant HBeAg negative chronic hepatitis B. Patients will receive PEGASYS 180 micrograms s.c. weekly for 48 weeks; following this, there will be a 48 week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>adult patients, 1865 years of age; HBeAg negative chronic hepatitis B; treated with lamivudine for &gt;=6 months; demonstrated lamivudine resistance; compensated liver disease. severe hepatic dysfunction; previous treatment with antivirals other than lamivudine; immunosuppressant treatment in past 6 months; coinfection with hepatitis A, C, or D virus or human immunodeficiency virus; medical condition associated with chronic liver disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>